The BIOEquality Agenda is a national effort in collaboration with our partners and member organizations in the biotechnology sector that aims to counteract the systemic inequality, injustice, and unfair treatment of underserved communities.
Promote Health Equity
Enhance clinical trial diversity by partnering with Contract Research Organizations and Minority Serving Institutions
Foster enhanced nutritional, environmental, and mental wellness opportunities in economically disadvantaged communities
Invest in the Current and Next Generation of Scientists
- Inventory and promote visibility of industry-sponsored minority training programs
- Establish STEM training best practices for underrepresented populations
- Create a network of minority scientists and engineers
- Facilitate a partnering network, including hiring of industry-trained minority scientists and engineers
Expand Opportunity for Women and Other Underrepresented Populations
- Enhance use of minority- and women-owned small businesses in biotech supply chains, to promote economic development of marginalized communities and especially those, hard hit by COVID-19
- Promote diversity of the NIH SBIR Grants
Join us from June 24th – 25th, 2021 at BIO’s first-ever summit on clinical trial diversity!
At the summit, BIO will convene stakeholders from across the clinical development spectrum to engage in meaningful discussion on advancing health equity in clinical trials. Because ensuring clinical trial diversity is not just at the heart of BIO’s Equality Agenda— it’s driving the future development and availability of innovative medical products.
The I AM BIO podcast spotlights diversity in clinical trials, vaccine education and overcoming the legacy of Tuskegee. Dr. Michelle interviews Tal Zaks, Chief Medical Officer of Boston biotech Moderna, about the company’s commitment to enroll people of color and vulnerable populations in its historic Phase 3 covid vaccine trial.